Vietnam's genomics market is entering a period of rapid expansion, driven by growing investment in precision medicine, advances in genetic testing technologies, and increasing demand for personalised healthcare. Industry analysts estimate the market is currently valued at US$180–220 million and is projected to reach US$420–550 million by 2030, representing an impressive annual growth rate of 18–22%.
This growth reflects Vietnam's broader healthcare transformation, with significant investment flowing into biotechnology, molecular diagnostics, genome sequencing and life sciences research. Healthcare providers are increasingly adopting genomic technologies to improve the diagnosis and treatment of cancer, inherited disorders, rare diseases and infectious diseases, while pharmaceutical companies are expanding the use of biomarkers and companion diagnostics to support targeted therapies.
A key catalyst is the growing adoption of Next-Generation Sequencing (NGS), which is becoming an essential tool across oncology, reproductive health, pharmacogenomics and clinical research. As costs continue to decline and clinical applications expand, genomic testing is becoming more accessible across both public and private healthcare systems.
Vietnam is also developing a strong domestic genomics ecosystem. Leading organisations such as Gene Solutions, Vinmec Healthcare System and MEDLATEC are investing heavily in advanced sequencing capabilities, clinical genomics and research partnerships, helping position the country as an emerging centre for precision healthcare in Southeast Asia.
The market presents significant opportunities for technology providers, laboratory equipment manufacturers, biotechnology companies, pharmaceutical organisations, healthcare providers and investors seeking to participate in one of Asia's fastest-growing life sciences sectors.
As Vietnam accelerates its journey towards precision medicine, genomics is expected to play an increasingly central role in transforming patient care, enabling earlier diagnosis, improving treatment outcomes and supporting the country's ambition to become a regional leader in healthcare innovation.
